Relmada Therapeutics (RLMD) Total Non-Current Liabilities (2014 - 2026)

Relmada Therapeutics (RLMD) has 8 years of Total Non-Current Liabilities data on file, last reported at $12.9 million in Q1 2026.

• Quarterly Total Non-Current Liabilities rose 190.59% year-over-year to $12.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.9 million (up 190.59% YoY) and the FY2025 annual result came in at $6.4 million, down 37.52% from the prior year.
• Total Non-Current Liabilities improved to $12.9 million in Q1 2026 per RLMD's latest filing, from $6.4 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $12.9 million in Q1 2026 and bottomed at $4.4 million in Q1 2025.
• The 3-year median for Total Non-Current Liabilities is $6.4 million (2025), against an average of $7.5 million.
• The widest annual swing landed in 2025, when Total Non-Current Liabilities plunged 37.52%; it then soared 190.59% in 2026.
• Tracing RLMD's Total Non-Current Liabilities over 3 years: stood at $10.3 million in 2024, then sank by 37.52% to $6.4 million in 2025, then jumped by 100.48% to $12.9 million in 2026.
• Per Business Quant, the three latest RLMD Total Non-Current Liabilities figures stand at $12.9 million (Q1 2026), $6.4 million (Q4 2025), and $5.2 million (Q3 2025).

Peer Comparison